1. Home
  2. NVRO vs BCTXW Comparison

NVRO vs BCTXW Comparison

Compare NVRO & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVRO
  • BCTXW
  • Stock Information
  • Founded
  • NVRO 2006
  • BCTXW N/A
  • Country
  • NVRO United States
  • BCTXW Canada
  • Employees
  • NVRO N/A
  • BCTXW 18
  • Industry
  • NVRO Medical/Dental Instruments
  • BCTXW Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVRO Health Care
  • BCTXW Health Care
  • Exchange
  • NVRO Nasdaq
  • BCTXW Nasdaq
  • Market Cap
  • NVRO N/A
  • BCTXW N/A
  • IPO Year
  • NVRO 2014
  • BCTXW N/A
  • Fundamental
  • Price
  • NVRO $5.08
  • BCTXW $0.30
  • Analyst Decision
  • NVRO Hold
  • BCTXW
  • Analyst Count
  • NVRO 14
  • BCTXW 0
  • Target Price
  • NVRO $9.80
  • BCTXW N/A
  • AVG Volume (30 Days)
  • NVRO 403.4K
  • BCTXW N/A
  • Earning Date
  • NVRO 11-11-2024
  • BCTXW N/A
  • Dividend Yield
  • NVRO N/A
  • BCTXW N/A
  • EPS Growth
  • NVRO N/A
  • BCTXW N/A
  • EPS
  • NVRO N/A
  • BCTXW N/A
  • Revenue
  • NVRO $426,098,000.00
  • BCTXW N/A
  • Revenue This Year
  • NVRO N/A
  • BCTXW N/A
  • Revenue Next Year
  • NVRO $2.50
  • BCTXW N/A
  • P/E Ratio
  • NVRO N/A
  • BCTXW N/A
  • Revenue Growth
  • NVRO 1.59
  • BCTXW N/A
  • 52 Week Low
  • NVRO $4.38
  • BCTXW N/A
  • 52 Week High
  • NVRO $22.64
  • BCTXW N/A
  • Technical
  • Relative Strength Index (RSI)
  • NVRO 46.41
  • BCTXW N/A
  • Support Level
  • NVRO $5.22
  • BCTXW N/A
  • Resistance Level
  • NVRO $6.14
  • BCTXW N/A
  • Average True Range (ATR)
  • NVRO 0.37
  • BCTXW 0.00
  • MACD
  • NVRO 0.04
  • BCTXW 0.00
  • Stochastic Oscillator
  • NVRO 34.16
  • BCTXW 0.00

About BCTXW BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: